An observational study in Mitral Valve Insufficiency, sponsored by Asan Medical Center. Recruiting at 1 site in South Korea. Open to participants aged 19 Years and older. Per ClinicalTrials.gov, last updated 2026-10-30.
Sponsored by Asan Medical Center · Observational
Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →
Among 11 studies in Mitral Valve Insufficiency with a site in Korea, Republic of — 3 open to participants now, 3 under way, none of them phase 3. Mitral Valve Insufficiency · Korea, Republic of.
Among the 11 studies in Mitral Valve Insufficiency with a site in Korea, Republic of, this one is one of 2 that started in 2024, is one of 5 observational ones, and was the 10th registered.
471 studies on the registry are indexed under Mitral Valve Insufficiency; 165 are open to participants now.
Browse Mitral Valve Insufficiency studies →3 of the 11 studies in Mitral Valve Insufficiency with a site in Korea, Republic of are open now. Recruiting first, the newest first:
Yonsei University · Sites in Korea, Republic of
Ages 19+
Konkuk University Medical Center · Sites in Korea, Republic of
Ages 19–65
A study can be open while its sites in Korea, Republic of have not opened yet or have stopped. Only those recruiting at a site in Korea, Republic of →
Of the 121 Mitral Valve Insufficiency studies recruiting now, 100 (83%) set no upper age limit and 6 (5%) stop at 75 or younger; 12 take children under 18; 1 takes healthy volunteers.
This study: 19 Years and older · all sexes · no healthy volunteers.
The full table on the hub →This tab as a report to print or save as PDF → With an account.
11 studies; the count open now beside each. This study's row is marked.
First in 1996; this study’s year is marked. 2 started in 2024.
By drug class, each counting the studies that test any of its medicines:
This study's planned enrollment of 200 is above the median of 159 across 170 observational studies indexed under Mitral Valve Insufficiency.
Median enrollment 70 across the 6 interventional studies, 200 across the 5 observational. Of the 8 that completed or were terminated, 1 (13%) have results posted.
This tab as a report to print or save as PDF → With an account.
1 of 11 have an industry lead sponsor. The 5 most frequent:
Asan Medical Center is the lead sponsor of 578 studies on the registry; 72 are open to participants now.
Asan Medical Center has 4 studies filed under Mitral Valve Insufficiency — fewer than ten, so there is no comparison to draw.
None of the studies under way reaches primary completion within a year.
Among the 11 studies in Mitral Valve Insufficiency with a site in Korea, Republic of, from their registry updates:
This tab as a report to print or save as PDF → With an account.
The purpose of this study is to evaluate the early and mid-term safety and performance of the MITRIS RESILIA mitral valve in Asian patients in a real-world setting
This study is a prospective, investigator-Investigator initiated, multicenter observational study that aims to competitively register 200 patients who have undergone mitral valve replacement surgery with the MITRIS RESILIA mitral valve at participating institutions to collect real clinical outcomes.
This study will collect data on clinical outcomes obtained during standard care for patients who undergo mitral valve replacement surgery using the MITRIS RESILIA mitral valve in South Korea.
The aim is to recruit 200 patients using the MITRIS RESILIA mitral valve (competitive recruitment, no more than 100 per institution) over a period of two years.
All patients registered in the registry will be followed for five years. Follow-up assessments will occur at 6 months, 1 year, 2 years, 3 years, and 5 years post-surgery. Including the 2-year registration period and 5 years of follow-up for result analysis, the total study duration is expected to be approximately 7.5 years. However, the overall duration may vary depending on the rate of participant registration.
Asian(REPUBLIC OF KOREA)
Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.
Exclusion Criteria:
Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
The study doctor’s estimate of how long someone is likely to live. Criteria use it so that people can stay in the study long enough for it to answer its question.
GFR (glomerular filtration rate) is how much blood the kidneys filter each minute. It is usually estimated from a blood test — eGFR, by formulas such as CKD-EPI or MDRD — and some studies ask for it to be measured directly instead. Usually given in mL/min/1.73 m².
Check the method, the units and the minimum the study states. A value of 90 or above is in the normal-or-high range, but kidney damage can show in other tests too.
Life expectancy
The study doctor’s estimate of how long someone is likely to live. Criteria use it so that people can stay in the study long enough for it to answer its question.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
GFR and eGFR (kidney filtering)
GFR (glomerular filtration rate) is how much blood the kidneys filter each minute. It is usually estimated from a blood test — eGFR, by formulas such as CKD-EPI or MDRD — and some studies ask for it to be measured directly instead. Usually given in mL/min/1.73 m².
Check the method, the units and the minimum the study states. A value of 90 or above is in the normal-or-high range, but kidney damage can show in other tests too.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Cardiovascular death
death that results from a disease of the heart or blood vessels
Time frame: 1 year post-surgery
Valve-related intervention
a procedure to repair or replace a diseased or faulty heart valve
Time frame: 1 year post-surgery
Structural valve deterioration and non-structural valve dysfunction
abnormality that's not intrinsic to the valve
Time frame: 1 year post-surgery
Peak and mean trans-mitral valve pressure gradient and effective orifice area
echocardiographic parameters used to assess mitral valve disease
Time frame: 6 month,1 year,2 year,3 year, 5year post-surgery
All-cause death
the total number of deaths from any cause in a given population over a specific period of time
Time frame: 6 month,1 year,2 year,3 year, 5year post-surgery
cardiovascular death
a death that results from a disease of the heart or blood vessels
Time frame: 6 month,1 year,2 year,3 year, 5year post-surgery
Valve-related death
any death that is caused by Structural valve deterioration,Nonstructural dysfunction,Valve thrombosis,Embolism,Bleeding event,Operated valve endocarditis,Death related to reintervention on the operated valve
Time frame: 6 month,1 year,2 year,3 year, 5year post-surgery
Stroke (ischemic or hemorrhagic)
a medical emergency that occurs when blood flow to the brain is blocked or a blood vessel in the brain bursts
Time frame: 6 month,1 year,2 year,3 year, 5year post-surgery
Hospitalization due to cardiovascular disease
a hospital admission with a defined cardiovascular cause
Time frame: 6 month,1 year,2 year,3 year, 5year post-surgery
Bleeding
BARC classification use.(A standardized tool for defining and categorizing bleeding events in clinical trials.)
Time frame: 6 month,1 year,2 year,3 year, 5year post-surgery
Infective endocarditis related to the mitral valve
a bacterial, viral, or fungal infection of the mitral valve leaflets
Time frame: 6 month,1 year,2 year,3 year, 5year post-surgery
Valve-related reintervention
any invasive procedure performed on the aortic valve, coronary button, or proximal aorta
Time frame: 6 month,1 year,2 year,3 year, 5year post-surgery
Structural valve deterioration or non-structural valve dysfunction
a type of valve dysfunction that involves permanent damage to the valve
Time frame: 6 month,1 year,2 year,3 year, 5year post-surgery
Valve thrombosis
a rare but life-threatening condition that occurs when a thrombus forms on a prosthetic heart valve and interferes with blood flow or valve function
Time frame: 6 month,1 year,2 year,3 year, 5year post-surgery
Plan to share: No
No publications or documents are linked to this record.
Started Dec 2024 (actual). Primary completion is estimated for Mar 2031, 75 months after the start.
Of 73 non-industry observational studies under Mitral Valve Insufficiency, half reached primary completion within 57 months of starting (the median), counting those still running; a quarter within 26 and three quarters within 192. This study's planned 75 months is above that.
Counting every sponsor, half of 85 studies reached it within 57 months; a quarter within 26 and three quarters within 192.
How these figures are worked out, and which studies are left out of them.
From the registry record's own update history. This site started tracking changes on Sep 25, 2026; for anything earlier, see the record history on ClinicalTrials.gov ↗
Eligibility is decided by the study team. Share this record with your doctor or contact the team directly.
Contact study teamGet an email when the registry record changes — status, dates, results — or when someone posts here.
Sign in to followQuestions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.
Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.
Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.